Vital metal - how can molybdenum be used biologically?
Mechanism of molybdenum insertase elucidated
The metal molybdenum is known as a component of molybdenum steel or also as molybdenum sulfide, an additive of motor oils. In addition to these technical applications, however, molybdenum also has an important biological function: In the cell, it occurs as a component of the so-called molybdenum cofactor. If mutations occur in an enzyme that is important for the biosynthesis of the molybdenum cofactor, the so-called molybdenum insertase, this has drastic and ultimately fatal consequences for the affected patient. A team of scientists led by Dr. Tobias Kruse from the Technical University of Braunschweig has now discovered how molybdenum insertase incorporates molybdenum into the molybdenum cofactor, thus providing the basis for a therapeutic approach. The results of the investigations have now been published in the journal "Nature Chemistry".
Molybdenum is a metal that is required for many technical applications. In the cell, it occurs in the form of the molybdenum cofactor, whose precursor is shown here in color. The mechanism by which molybdenum is incorporated into this precursor was unknown for a long time.
Tobias Kruse/Hintergrund istock.com/davidf
The molybdenum cofactor is - to put it simply - composed of an organic and an inorganic component, molybdenum. While the biosynthesis of the organic component is well understood, it has long been unclear how the molybdenum is "incorporated" into the organic component.
To find out, scientists in Dr. Tobias Kruse's team at TU Braunschweig have created a working model based on a specific patient mutation in molybdenum insertase. The molybdenum insertase is then defective. The metal molybdenum can therefore no longer be made available to the body in the form of the molybdenum cofactor. Affected patients develop epilepsy-like seizures on average within 24 hours after birth. This leads to the massive death of nerve cells, which ultimately results in the death of affected individuals at an average age of three years. This disease is known as molybdenum cofactor deficiency and has so far been difficult to treat.
The "reconstruction" of the mutation in the defective molybdenum insertase of the patient was then the basis for the following research work for Dr. Tobias Kruse and his colleagues. In cooperation with Professor Douglas C. Rees at the California Institute of Technology (USA), the protein structure of molybdenum insertase was elucidated, leading to the discovery of a new, previously unknown step in the biosynthetic pathway of the molybdenum cofactor. In cooperation with Professor Martin L. Kirk (Department of Chemistry and Chemical Biology, The University of New Mexico, Albuquerque, USA), the mechanism of molybdenum insertion, i.e. the process by which molybdenum is incorporated into the organic component of the molybdenum cofactor, was then elucidated.
About 20 years ago, the mechanism of molybdenum insertion was already described, but for the synthesis of artificial molybdenum model compounds that can replicate the vital function of the molybdenum cofactor "in the test tube". The researchers have now shown for the first time that the final step of molybdenum cofactor biosynthesis in the cell follows the same scheme as the synthesis of molybdenum model compounds in the chemistry lab. It is now known that this mechanism underlies not only human but also plant and fungal molybdenum insertion. This indicates that this process arose very early in the evolution of living organisms.
However, the most important aspect of this work has undoubtedly been named by one of the peer reviewers of the paper now published in Nature Chemistry: With the knowledge of the mechanistic details of how molybdenum is functionalized - i.e. made biologically usable - in the cell, the foundations have now been laid for compensating for the lack of molybdenum insertase activity in affected patients. Suitable model compounds have already been and are being developed and synthesized in the group of Prof. Carola Schulzke (University of Greifswald) and are to be characterized in more detail at the TU Braunschweig for applicability to therapy of molybdenum cofactor deficiency.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
